MedTrace Logo

Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia

NCT06702098 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-11-22

No results posted yet for this study

Summary

This is a clinical study on the use of iNK cells for the treatment of refractory relapsed acute myeloid leukemia.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

DRUG

iNK cells

Induced pluripotent stem cells derived NK cells.

Sponsors & Collaborators

  • Fifth Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Guangzhou Ruixin Biotechnological Co., LTD

    lead INDUSTRY

Principal Investigators

  • Huo Tan, MD · Fifth Affiliated Hospital of Guangzhou Medical University

  • Runhui Zheng, MD · Fifth Affiliated Hospital of Guangzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-25
Primary Completion
2026-08-31
Completion
2026-11-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06702098 on ClinicalTrials.gov